

Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study

Philippe Ruzsniowski¹; Martyn E. Caplin²; Juan W. Valle³; Catherine Lombard-Bohas⁴; Graeme Poston⁵; Petros Perros⁶; Luboš Holubec⁷; Gianfranco Delle Fave⁸; Denis Smith⁹; Patricia Niccoli¹⁰; Pascal Maisonobe¹¹; Edda Gomez-Panzani¹²

¹Beaujon Hospital, F-92118 Clichy, France

²Royal Free Hospital, London NW3 2QG, UK

³Christie NHS Foundation Trust, Manchester M20 4BX, UK

⁴Edouard-Herriot Hospital, 69003 Lyon, France

⁵University Hospital Aintree, Liverpool L9 7AL, UK

⁶Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK

⁷Teaching Hospital Plzen, 301 00 Plzen–Bory, Czech Republic

⁸Ospedale Sant' Andrea, 00189 Rome, Italy

⁹Saint André Hospital, 33000 Bordeaux, France

¹⁰CHU Timone, 13005 Marseille, France

¹¹Ipsen, 92100 Boulogne-Billancourt, France

¹²Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ 07920, USA

Background: CS associated with NETs can have a negative impact on patients' QoL. Here, QoL data are evaluated from the SymNET study.

Methods: The SymNET study was a large observational trial involving patients with a NET and a history of CS-related diarrhea (NCT01234168). Patients had been treated with LAN for >3 months. Patient-reported outcomes were assessed at a routine clinic visit. The primary endpoint was patient satisfaction with diarrhea control (PSD). Symptoms were evaluated using medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ-C30; higher scores = better QoL) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control.

Results: Among 273 patients enrolled, 76% [95% CI: 70, 81] were 'completely' or 'rather' satisfied with diarrhea control. There was a clinically significant reduction in stool number and statistically significant improvements in urgency, leakage, and associated pain since the initiation of LAN. Scores for the QLQ-C30 global health status were high (mean [SD] 65.5 [22.1], median [range] 66.7 [0–100]), while scores for the QLQ-GI.NET21 endocrine and gastrointestinal subscales were low (endocrine, mean [SD] 19.4 [21.3], median [range] 11.1 [0–100]; gastrointestinal, mean [SD] 22.9 [17.8], median [range] 20.0 [0–87]). Patients who expressed a high PSD scored well on their overall rating of QoL (Table); in total, 70% of patients who were 'rather' or 'completely' satisfied had 'good', 'very good', or 'excellent' QoL.

Conclusion: In a real-world setting, CS symptom control with LAN treatment translates into favorable levels of satisfaction among patients with NETs. Higher satisfaction levels were consistent with higher global health QoL scores.

Table. QoL according to PSD

	n (%)		
	'Rather' or 'completely' satisfied (n=200)	Neither satisfied nor dissatisfied (n=46)	'Rather' or 'completely' dissatisfied (n=18)
Overall QoL			
Very poor, poor, or slightly poor	28 (14)	12 (26)	5 (28)
Neither poor nor good	32 (16)	12 (26)	6 (33)
Good, very good, or excellent	140 (70)	22 (48)	7 (39)